Deep brain stimulation to the medial forebrain bundle for depression- long-term outcomes and a novel data analysis strategy
Introduction
About 30% of patients suffering from major depressive disorder (MDD) fail to respond to established pharmacological, psychotherapeutic or somatic treatments [1] and are then classified as having a treatment-resistant depression (TRD). Deep brain stimulation (DBS) at different brain targets is currently under research as a possible treatment option for TRD. In small pilot studies, antidepressant effects of DBS at the subgenual cingulate gyrus (Cg25) [2], [3], [4], the anterior limb of the capsula interna (ALIC) [5], [6] and the nucleus accumbens (Nacc) [7], [8] are described. A significant response, defined as a reduction of symptoms over 50%, was reached in about 50% of the patients after 12 months of DBS treatment [6], [9], [10], [11], [12], [13]. First larger clinical trials including a placebo phase stimulating ALIC [14] or Cg25 [15] failed to prove efficacy underlining the importance of a careful analysis of pilot studies to optimize the study design in randomized-controlled studies (for a detailed comment see Ref. [16]). Recently, DBS at the supero-lateral branch of the medial forebrain bundle (slMFB) was presented as a new DBS target. A more rapid antidepressant response in seven patients of the present sample with a response rate of 85% after three months DBS was obtained in an interim analysis [17] (for a detailed description of mode of action see Refs. [18], [19], [20]). Long-term data on this target are lacking.
Traditionally, data in depression studies on patients that are not resistant to treatment is reported at predefined study end points, mostly six to twelve weeks, due to the assumed latency of clinical response to pharmacotherapy [21]. In the TRD population, different ways of data analysis are suggested [22], [23]. Patients suffering from TRD cannot be cured –in the sense of a stable absence of symptoms-within short intervals and response to any treatment approach varies during the process of the study. Assessing at fixed, somewhat arbitrarily chosen end points might be misleading [23] and cannot convey all information about the impact of the treatment [24]. From the patient's as well as from the clinician's perspective, the benefit from a treatment is the degree of improvement over time. Therefore, we have analyzed our 12 months data both in the conventional way as well as in a timeline analysis. Timeline analyses are standard in other fields such as endocrinology [25], cardiology [26] and diabetes research [27]. A symptom reduction of 50% from baseline is conventionally used as response criterion. We propose a larger differentiation of this arbitrarily chosen criterion for the population of TRD (see Refs. [10], [28], for a detailed discussion of the response criterion, [29]).
In this study, antidepressant effects of DBS to the slMFB for up to four years are described. Anxiety, social functioning, quality of life, safety and cognition are reported at fixed time points and with timeline data analysis.
Section snippets
Patients
Three-month follow-up data of seven patients have recently been published [30]. One further patient has been included in this study because we had a raise in funding, he received the same protocol; so eight patients received slMFB DBS for 48 months. All patients suffered at baseline from severe treatment-resistant depression according to DSM-IV [SCID-I & II] [31]. One bipolar patient was included in this study (last manic episode occurred 23 years ago). Three raters analyzed clinical records.
Demographic and clinical characteristics
Eight patients between 30 and 55 years of age with a current depressive episode of 7.1 ± 4.48 years were included in this study (see Table 1 for demographic and clinical details). All patients were diagnosed having severe TRD with an ATHF score of 3 in the current episode. A score of “3” is the threshold for considering a trial adequate and the patient resistant to that treatment. Before DBS implantation, patients were treated with 18.8 ± 7.03 antidepressant medications, had received ECT and
Antidepressant efficacy - conventional analysis
Long-term antidepressant effects following bilateral supero-lateral branch of the medial forebrain bundle (slMFB)-DBS in patients suffering from severe TRD have been demonstrated in this study. 75% of the patients responded to the slMFB-DBS at twelve months. There was a significant reduction in depression score in each month compared to the baseline in all depression scales (see Ref. [45] for a meta-analysis of the correlation of different measures of depression in long-term studies). The
Conclusions
The slMFB appears to be a promising target for DBS in TRD. The strong antidepressant effect was sustained up to four years with few side effects and could be detected in a small sample. Traditionally, placebo-controlled comparison-group trials are the gold standard in clinical studies. For TRD-DBS, a high-risk interventional treatment for chronically ill patients, study designs have to be carefully balanced with ethical criteria, especially in the light of the failure of the two large
Acknowledgment and conflict of interest
This investigator-initiated study was funded in part (DBS device, battery exchange, medical costs, and limited support for study nurse) by a grant of Medtronic. to Dr. Schlaepfer and Dr. Coenen. All other authors state no conflict of interest. The sponsor had no influence on design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
We especially thank Dr. Ali Sarem-Aslani, Medtronic Inc. for his many
References (57)
- et al.
Deep brain stimulation for treatment-resistant depression
Neuron
(2005) - et al.
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Biol Psychiatry
(2008) - et al.
Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression
Biol Psychiatry
(2009) - et al.
Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression
Biol Psychiatry
(2010) - et al.
Deep brain stimulation for treatment-resistant depression: systematic review of clinical outcomes
Neurotherapeutics
(2014) Deep brain stimulation for major depression-steps on a long and winding road
Biol Psychiatry
(2015)- et al.
Rapid effects of deep brain stimulation for treatment resistant major depression
Biol Psychiatry
(2013) - et al.
Salivary cortisol and depression in public sector employees: cross-sectional and short term follow-up findings
Psychoneuroendocrinology
(2014) - et al.
Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting
Am J Cardiol
(2015) - et al.
Rapid effects of deep brain stimulation for treatment-resistant major depression
Biol Psychiatry
(2013)
Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change
Psychoneuroendocrinology
Meta-analysis of the changes in correlations between depression instruments used in longitudinal studies
J Affect Disord
Deep brain stimulation of the medial forebrain bundle: Distinctive responses in resistant depression
J Affect Disord
Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
Biol Psychiatry
Predicting placebo response in adolescents with major depressive disorder: the Adolescent Placebo Impact Composite Score (APICS)
J Psychiatr Res
Longitudinal course of symptom severity and fluctuation in patients with treatment-resistant unipolar and bipolar depression
Psychiatry Res
Cross-species affective functions of the medial forebrain bundle-Implications for the treatment of affective pain and depression in humans
Neurosci Biobehav Rev
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
Am J Psychiatry
Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months
J Nerv Ment Dis
Use of deep brain stimulation in treatment-resistant depression
Clevel Clin J Med
Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology
official Publ Am Coll Neuropsychopharmacol
Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy
Neuropsychopharmacology
A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression
J Neurosurg
Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression
Int J Neuropsychopharmacol
Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years
Am J Psychiatry
Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression
Arch Gen Psychiatry
720-A randomized sham-Controlled trial of DBS of the VC/VS for treatment-resistant depression
Biol Psychiatry
Individual fiber anatomy of the subthalamic region revealed with diffusion tensor imaging: a concept to identify the deep brain stimulation target for tremor suppression
Neurosurgery
Cited by (111)
Input-output relation of midbrain connectomics in a rodent model of depression
2024, Journal of Affective DisordersAcupuncture for treating adolescent depression: Study protocol for a randomized controlled trial
2023, Medicine in Novel Technology and DevicesWhat do we know about astrocytes and the antidepressant effects of DBS?
2023, Experimental NeurologyOptogenetic stimulation of transmission from prelimbic cortex to nucleus accumbens core overcomes resistance to venlafaxine in an animal model of treatment-resistant depression
2023, Progress in Neuro-Psychopharmacology and Biological Psychiatry